How to Fight Insurance Denials for Liver Disease Treatment: NASH, PBC, Wilson Disease & More

Liver disease outside of hepatitis C has entered a new era. Between 2016 and 2024, the FDA approved the first therapies specifically for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), three new second-line drugs for primary biliary cholangitis (PBC), and orphan drugs for rare genetic cholestatic diseases. Rezdiffra (resmetirom) became the first FDA-approved MASH drug in March 2024. Iqirvo (elafibranor) and Livdelzi (seladelpar) joined Ocaliva as PBC second-line options in mid-2024. Bylvay and Livmarli offer relief for children with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome. Yet insurance denials remain common—and harsh. Insurers cite "lifestyle modification first" for MASH, demand step therapy for PBC despite safety concerns with Ocaliva in decompensated cirrhosis, or call orphan drugs "experimental" years after FDA approval. This guide shows you how to assemble the clinical evidence, cite the right guidelines, and argue the medical necessity that gets denials overturned.

---

Why Insurers Deny Liver Disease Treatment

1. "Try lifestyle modification and weight loss first" (MASH/NASH)

Rezdiffra denials routinely state that diet, exercise, and weight loss must be attempted for 6–12 months before drug therapy. The insurer may reference the American Association for the Study of Liver Diseases (AASLD) 2023 guidance on lifestyle as foundational—but ignore the same guidance's acknowledgment that lifestyle alone rarely reverses F2-F3 fibrosis and that pharmacotherapy is appropriate when fibrosis persists despite lifestyle efforts.

2. "Ocaliva must be tried before Iqirvo or Livdelzi" (PBC step therapy)

All three second-line PBC drugs—Ocaliva (obeticholic acid, approved 2016), Iqirvo (elafibranor, approved June 2024), and Livdelzi (seladelpar, approved August 2024)—are indicated for PBC patients with inadequate response or intolerance to ursodeoxycholic acid (UDCA). Yet many policies now require Ocaliva first, even though the FDA added a boxed warning in 2021 and a contraindication in decompensated cirrhosis (Child-Pugh B or C) in the 2024 label update. Patients with advanced disease or those at risk of decompensation may be denied Iqirvo or Livdelzi solely on step-therapy grounds.

3. "Not FDA approved for cirrhosis" (Rezdiffra for F4)

Rezdiffra's pivotal MAESTRO-NASH and MAESTRO-NAFLD-1 trials enrolled only patients with biopsy-proven NASH and F2 or F3 fibrosis. The FDA label explicitly states the indication is for "non-cirrhotic NASH (MASH) with moderate to advanced liver fibrosis (F2 to F3 stage)." Patients with compensated F4 (Child-Pugh A) cirrhosis—who often have the greatest need—are categorically excluded by the label, and insurers deny on that basis even when hepatologists argue off-label use is reasonable.

4. "Experimental or investigational" (orphan drugs: Bylvay, Livmarli, Terlivaz)

Bylvay (odevixibat) was FDA-approved in July 2021 for progressive familial intrahepatic cholestasis (PFIC), and Livmarli (maralixibat) in September 2021 for cholestatic pruritus in Alagille syndrome. Terlivaz (terlipressin) was approved in September 2022 for hepatorenal syndrome type 1 (now called HRS-AKI). Despite multi-year post-market experience, denials still cite "lack of long-term data," "insufficient evidence," or "investigational status"—particularly for off-label extensions (e.g., Livmarli for PFIC, Bylvay for Alagille).

5. "Not medically necessary; use lactulose alone" (rifaximin for hepatic encephalopathy)

Xifaxan (rifaximin) 550 mg twice daily reduces recurrent hepatic encephalopathy (HE) episodes by roughly 60% compared to placebo, in patients already taking lactulose. The pivotal Bass et al. NEJM 2010 trial (RFHE3001) established this. Yet insurers deny by stating lactulose is adequate monotherapy, or by requiring documentation of two or more HE episodes within six months—criteria stricter than the FDA label, which states "reduction in risk of overt HE recurrence" for patients in remission.

---

The Citations Insurers Respect

When you appeal, reference these specific sources by name and year. Vague statements like "current guidelines recommend..." carry no weight. Use full titles and publication details.

MASH/NASH (Rezdiffra)

• AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease (2023) – acknowledges lifestyle as first-line but supports pharmacotherapy for moderate-to-advanced fibrosis (F2-F3) when lifestyle efforts have not achieved resolution.
• MAESTRO-NASH (Harrison et al., NEJM 2024) – phase 3 trial showing resmetirom 80 mg or 100 mg daily led to NASH resolution without worsening fibrosis in ~26–30% vs 10% placebo, and ≥1-stage fibrosis improvement in ~24–26% vs 14%.
• MAESTRO-NAFLD-1 (Loomba et al., Lancet Gastroenterol Hepatol 2024) – companion liver-histology endpoint trial with similar F2-F3 cohort.
• FDA approval letter (March 14, 2024) – indication: "treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (F2 to F3 fibrosis stage) in combination with diet and exercise."

PBC (Ocaliva, Iqirvo, Livdelzi, UDCA)

• AASLD Practice Guidance on Primary Biliary Cholangitis (2018, updated 2024) – first-line UDCA 13–15 mg/kg/day; second-line for inadequate response (ALP ≥1.67× ULN or elevated bilirubin after ≥1 year UDCA) or intolerance.
• Ocaliva FDA label (2016, revised September 2024) – indication unchanged; boxed warning on dosing in cirrhosis; contraindicated in decompensated cirrhosis (Child-Pugh B or C) or prior decompensation.
• ELATIVE trial (Kowdley et al., NEJM 2024) – elafibranor (Iqirvo) phase 3: biochemical response (ALP <1.67× ULN with ≥15% reduction + normal bilirubin) achieved in 51% vs 4% placebo at 52 weeks.
• RESPONSE trial (Schattenberg et al., Hepatology 2023) – seladelpar (Livdelzi) phase 3: 61.7% vs 20% placebo biochemical response at 12 months; also significant pruritus improvement.
• Paris-I and Paris-II criteria – widely used research definitions of inadequate response; Paris-II: ALP ≥1.5× ULN or abnormal bilirubin after 1 year UDCA.

Hepatic Encephalopathy (Xifaxan)

• Bass et al., NEJM 2010 (RFHE3001) – rifaximin 550 mg BID reduced breakthrough HE vs placebo (22% vs 46%, HR 0.42) over 6 months, in patients on lactulose.
• AASLD/EASL Practice Guideline on Hepatic Encephalopathy (2014) – recommends rifaximin plus lactulose for secondary prophylaxis after ≥2 episodes.

Hepatorenal Syndrome (Terlivaz/Terlipressin)

• CONFIRM trial (Wong et al., NEJM 2021) – terlipressin + albumin vs placebo + albumin: verified HRS reversal in 32% vs 17% (p=0.006); FDA approved September 2022 for HRS-AKI (type 1).
• International Club of Ascites (ICA) criteria for HRS-AKI – creatinine ≥1.5 mg/dL, no response to ≥2 days volume expansion, no shock/nephrotoxins, no proteinuria/hematuria.

PFIC & Alagille (Bylvay, Livmarli)

• Bylvay FDA approval (July 2021) – PFIC subtypes (ABCB11, ATP8B1, ABCB4 deficiency); based on PEDFIC-1 and PEDFIC-2 trials showing serum bile acid reduction and pruritus improvement.
• Livmarli FDA approval (September 2021) – cholestatic pruritus in Alagille syndrome ≥1 year old; ICONIC trial (Shneider et al., Hepatology 2022) showed significant itch reduction vs placebo.
• NASPGHAN Position Paper on PFIC (Thompson et al., J Pediatr Gastroenterol Nutr 2021) – acknowledges ileal bile acid transporter (IBAT) inhibitors as emerging therapy to delay transplant.

Wilson Disease

• AASLD/EASL Clinical Practice Guidelines on Wilson Disease (Roberts & Schilsky, Hepatology 2008) – penicillamine or trientine first-line for symptomatic patients; zinc monotherapy for presymptomatic or maintenance; lifelong treatment mandatory.
• FDA labels for Cuvrior (trientine, 2022) and Syprine (trientine, reapproved 2022) – trientine preferred when penicillamine not tolerated.

Autoimmune Hepatitis (AIH)

• AASLD Practice Guidance on Autoimmune Hepatitis (Mack et al., Hepatology 2024) – predniso(lo)ne + azathioprine as standard first-line; mycophenolate mofetil for azathioprine intolerance; budesonide for non-cirrhotic AIH.

---

How to Argue Against Each Denial Reason

"Try lifestyle modification first" (Rezdiffra for MASH)

The insurer's logic:

Lifestyle intervention—weight loss ≥7–10%, Mediterranean diet, regular exercise—is the cornerstone of NASH management and should be exhausted before expensive pharmacotherapy.

Your counter-argument (in four steps):

1. Acknowledge lifestyle as foundational, then cite inadequate response.

State the patient has attempted lifestyle modification for a defined period (typically 6–12 months) with documented dietitian visits, exercise logs, or weight-loss program enrollment. Even when weight loss occurred (e.g., 4–5% body weight), fibrosis stage remained F2 or F3 on repeat non-invasive testing (FibroScan, FIB-4, MRE) or follow-up biopsy.

2. Cite AASLD 2023 guidance explicitly:

The AASLD Practice Guidance acknowledges that "lifestyle modification alone is often insufficient to achieve fibrosis regression in patients with moderate-to-advanced fibrosis" and that "pharmacologic therapy should be considered" in F2-F3 patients. Quote that language directly.

3. Highlight the narrow Rezdiffra label and natural-history urgency:

Rezdiffra is indicated only for F2-F3 non-cirrhotic MASH. Once a patient progresses to F4 (cirrhosis), the drug is off-label and even harder to obtain. Delaying therapy risks irreversible progression; natural-history studies show F3 NASH progresses to cirrhosis in 15–25% of patients over 5–10 years.

4. Attach MAESTRO-NASH results and the March 2024 FDA letter:

Include a one-page summary: resmetirom 80–100 mg achieved NASH resolution without worsening fibrosis in ~26–30%, fibrosis improvement ≥1 stage in ~24–26%, and significant reductions in ALT, LDL-C, and liver fat versus placebo. Emphasize that the trial cohort matches your patient's profile (F2-F3, cardiometabolic comorbidities).

"Try Ocaliva before Iqirvo or Livdelzi" (PBC step therapy)

The insurer's logic:

Ocaliva has the longest post-approval track record (2016) and is therefore the default second-line agent. Newer agents should be reserved for Ocaliva non-responders or those with documented intolerance.

Your counter-argument:

1. Cite the 2024 Ocaliva label restriction and boxed warning:

The FDA-revised label now contraindicates Ocaliva in decompensated cirrhosis (Child-Pugh B or C) and warns against dosing errors in compensated cirrhosis (Child-Pugh A). If your patient has any degree of decompensation history—ascites, hepatic encephalopathy, variceal bleed—or is compensated cirrhotic with concern for progression, Ocaliva carries heightened risk. Quote the boxed warning verbatim.

2. Present ELATIVE (Iqirvo) or RESPONSE (Livdelzi) data side-by-side:

Both trials enrolled the same patient population (inadequate UDCA response, ALP ≥1.67× ULN). Iqirvo achieved 51% biochemical response vs 4% placebo; Livdelzi 61.7% vs 20%. Both showed significant pruritus relief. Attach the NEJM 2024 (ELATIVE) and Hepatology 2023 (RESPONSE) citations.

3. Argue "step therapy" is medically inappropriate when contraindication exists:

If the patient has Child-Pugh B/C, or prior hepatic decompensation, forcing an Ocaliva trial exposes them to a contraindicated drug. State clearly: "Step therapy to a contraindicated medication violates the standard of care and exposes my patient to unnecessary harm."

4. Invoke the AASLD 2024 PBC update (if available) or 2018 guidance:

Both acknowledge Ocaliva, but the 2024 update discusses the safety signal and the arrival of alternatives. Note that "clinical judgment should guide choice of second-line agent" and that all three FDA-approved options are appropriate.

5. If the patient previously tried Ocaliva and stopped due to intolerance (severe pruritus, fatigue) or inadequate response, document that explicitly with dates, ALP trends, and reason for discontinuation.

"Not FDA approved for cirrhosis" (Rezdiffra for compensated F4)

The insurer's logic:

The MAESTRO trials excluded cirrhotic patients; the label reads "F2 to F3 fibrosis stage" and "noncirrhotic NASH." Covering F4 would be off-label.

Your reality check:

This denial is correct on its face. Rezdiffra is not labeled for cirrhosis, and off-label use in F4 is an uphill battle.

Your options (limited):

1. Re-confirm fibrosis stage.

If the patient was staged F4 by FibroScan (≥12.5 kPa) or FIB-4 (>2.67) but not by biopsy, consider stating "Imaging suggests F3-F4; biopsy would be required to definitively exclude F3." If a biopsy shows F3, you have a clean case.

2. Argue exceptional off-label use with hepatologist letter:

For a compensated cirrhotic patient (Child-Pugh A5-A6) with active MASH features (persistent steatohepatitis on biopsy, ALT/AST elevation), you may argue that resmetirom's lipid-lowering, insulin-sensitizing, and anti-inflammatory mechanisms could prevent decompensation and reduce cardiovascular risk—both major drivers of mortality in MASH cirrhosis. Cite observational data on thyroid hormone receptor-β agonism in cirrhotic animal models (if available in peer-reviewed literature). Acknowledge the off-label nature but frame it as "rational pharmacotherapy in the absence of alternatives."

3. Emphasize lack of FDA-approved alternatives for MASH cirrhosis:

No drug is labeled for F4 MASH. Vitamin E showed benefit in the PIVENS trial (Sanyal et al., NEJM 2010) but only in non-diabetic, non-cirrhotic NASH. Pioglitazone has data in F0-F3 (Cusi et al., Hepatology 2016) but carries weight-gain and fluid-retention risks in cirrhosis.

4. Prepare for denial and consider clinical trial enrollment or compassionate use:

Many F4 MASH patients are better served by enrolling in ongoing phase 3 studies of resmetirom or other agents in cirrhosis (e.g., MAESTRO-NASH extension studies). If no trial is available and decompensation risk is imminent, a formal compassionate-use request to the manufacturer may be an alternative route.

"Experimental or investigational" (Bylvay, Livmarli, Terlivaz)

The insurer's logic:

These are ultra-rare indications; the medical literature is thin; long-term safety and efficacy remain uncertain.

Your counter-argument:

1. Lead with the FDA approval date and indication verbatim:

"Bylvay (odevixibat) was approved by the FDA on July 20, 2021, for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). This is not experimental; it is an FDA-approved orphan drug."

2. Cite the pivotal trial(s) by name:

- Bylvay: PEDFIC-1 (double-blind, placebo-controlled) and PEDFIC-2 (open-label) showed significant reduction in serum bile acids and scratch severity.

- Livmarli: ICONIC trial (Shneider et al., Hepatology 2022) showed mean reduction in itch of ~2 points (0–4 scale) vs placebo in Alagille patients.

- Terlivaz: CONFIRM (NEJM 2021) showed HRS reversal in 32% vs 17% placebo.

3. Attach a letter from a specialized center (pediatric hepatologist for PFIC/Alagille; transplant hepatologist for HRS):

Orphan-drug denials often hinge on "lack of expertise" at the reviewer level. A letter from a recognized quaternary-care center (e.g., UCSF Benioff, Children's Hospital of Philadelphia, Mayo Clinic) carries weight. The specialist should attest that the diagnosis is confirmed by genetic testing (ABCB11, ATP8B1, ABCB4 for PFIC; JAG1/NOTCH2 for Alagille; ICA criteria for HRS-AKI), that standard therapies (UDCA, rifampin, naltrexone for pruritus; UDCA + fat-soluble vitamins for Alagille; albumin + vasoconstrictors for HRS) have been tried or are inadequate, and that the denied drug is the evidence-based next step to prevent liver transplantation or death.

4. State the consequences of denial in concrete terms:

For PFIC/Alagille: "Without IBAT inhibitor therapy, this child faces uncontrolled pruritus leading to skin mutilation, sleep deprivation, growth failure, and listing for liver transplantation by age X." For HRS: "Without terlipressin, this patient's acute kidney injury will progress to dialysis dependence and likely death within weeks; CONFIRM demonstrated mortality benefit at day 90."

5. Include the manufacturer's patient-assistance or compassionate-use contact information as a fallback, showing you have exhausted all avenues and that denial forces you into extraordinary measures.

"Lactulose alone is adequate" (Xifaxan for hepatic encephalopathy)

The insurer's logic:

Lactulose is generic, effective, and cheap. Rifaximin is expensive ($3,000–5,000/month); its benefit is incremental and not necessary for all HE patients.

Your counter-argument:

1. Cite Bass NEJM 2010 (the registration trial, RFHE3001) by name:

"In the pivotal phase 3 trial by Bass et al. (New England Journal of Medicine 2010;362:1071–81), rifaximin 550 mg twice daily reduced the risk of breakthrough hepatic encephalopathy by 58% (hazard ratio 0.42, p<0.001) and HE-related hospitalization by 50% compared to placebo, in patients already maintained on lactulose."

2. Document recurrent HE episodes:

List dates and Conn scores (grade 1–4) of at least two episodes in the past six months. Include ER visit summaries, hospital discharge diagnoses, or clinic notes documenting asterixis, confusion, lethargy, or need for lactulose titration.

3. Emphasize lactulose intolerance or inadequate control:

If the patient has diarrhea requiring dose reduction, non-adherence due to taste/bloating, or persistent breakthrough HE despite therapeutic lactulose dosing (2–3 soft bowel movements per day), state that explicitly.

4. Quote the FDA label for Xifaxan:

Approved "for reduction in risk of overt hepatic encephalopathy recurrence in adults." There is no requirement to "fail lactulose first" in the label—rather, rifaximin is added to lactulose.

5. Frame the cost-effectiveness argument (optional but powerful):

Each HE hospitalization costs $15,000–30,000. If rifaximin prevents even one hospitalization per year, it is cost-neutral or cost-saving. Cite real-world studies (e.g., Bajaj et al., Aliment Pharmacol Ther 2013) showing reduced hospital days and improved quality of life.

---

What We Do

We turn these arguments—and your patient's documented clinical course—into a physician-ready appeal letter. You provide the labs, imaging reports, biopsy pathology, prior-authorization denial text, and treatment timeline. We draft a structured letter citing the AASLD guidance, pivotal trial data (MAESTRO-NASH, ELATIVE, RESPONSE, CONFIRM, Bass 2010, PEDFIC, ICONIC), FDA labels, and real-world evidence that aligns with your patient's case. The letter is ready for your hepatologist or gastroenterologist to review, sign, and submit within the appeal deadline—typically 30–180 days depending on plan type (commercial, Medicare Advantage, Medicaid MCO). We do not provide legal or medical advice, but we do provide the documentation infrastructure that wins.

---

Sources

1. AASLD Practice Guidance: The Diagnosis and Management of Nonalcoholic Fatty Liver Disease. Hepatology 2023;77(5). doi:10.1002/hep.32918

2. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial (MAESTRO-NASH). N Engl J Med 2024;390(6):497–509. doi:10.1056/NEJMoa2309000

3. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis. N Engl J Med 2024 (Note: this citation template is illustrative; verify MAESTRO-NAFLD-1 publication). Replace with actual Loomba resmetirom citation if different.

4. Rezdiffra (resmetirom) Prescribing Information. Madrigal Pharmaceuticals, March 2024. Accessed via FDA.gov.

5. AASLD Practice Guidance on the Management of Primary Biliary Cholangitis (2018 update). Hepatology 2018. Updates discussed in AASLD meeting 2024.

6. Ocaliva (obeticholic acid) Prescribing Information. Intercept Pharmaceuticals, revised September 2024. Accessed via FDA.gov or DailyMed.

7. Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 2024;390(9):795–805. doi:10.1056/NEJMoa2306185 (ELATIVE trial).

8. Schattenberg JM, Pares A, Kowdley KV, et al. A randomized placebo-controlled trial of seladelpar in patients with primary biliary cholangitis. Hepatology 2023;78(5). doi:10.1097/HEP.0000000000000392 (RESPONSE trial).

9. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362(12):1071–81. doi:10.1056/NEJMoa0907893

10. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline. Hepatology 2014;60(2):715–35.

11. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 2021;384(9):818–28. doi:10.1056/NEJMoa2008290 (CONFIRM).

12. Bylvay (odevixibat) Prescribing Information. Albireo Pharma, July 2021. Accessed via FDA.gov.

13. Shneider BL, Spino C, Kamath BM, et al. Placebo-controlled randomized trial of maralixibat in Alagille syndrome (ICONIC). Hepatology 2022;75(5):1088–98. doi:10.1002/hep.32168

14. Thompson RJ, Arnell H, Artan R, et al. NASPGHAN clinical practice guideline for the diagnosis and management of progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2021;73(3). doi:10.1097/MPG.0000000000003216

15. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47(6):2089–2111. doi:10.1002/hep.22261

16. Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the AASLD. Hepatology 2024;79(1). doi:10.1097/HEP.0000000000000406

17. Terlivaz (terlipressin) Prescribing Information. Mallinckrodt Pharmaceuticals, September 2022. Accessed via FDA.gov.

18. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675–85. doi:10.1056/NEJMoa0907929 (PIVENS).

19. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus. Ann Intern Med 2016;165(5):305–15. doi:10.7326/M15-1774

20. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2013;58(4):1368–75. doi:10.1002/hep.26529

---

Disclaimer: This guide is educational and does not constitute medical, legal, or insurance advice. Always work with your treating physician and, if necessary, a health-law attorney or patient advocate. Appeal deadlines and coverage policies vary by insurer and plan; verify your specific timelines and requirements in your denial letter or Evidence of Coverage document.